company background image
STSA

Satsuma Pharmaceuticals NasdaqGM:STSA Stock Report

Last Price

US$7.32

Market Cap

US$231.2m

7D

5.8%

1Y

45.8%

Updated

24 Sep, 2022

Data

Company Financials +
STSA fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

STSA Stock Overview

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines.

Satsuma Pharmaceuticals Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Satsuma Pharmaceuticals
Historical stock prices
Current Share PriceUS$7.32
52 Week HighUS$8.08
52 Week LowUS$2.51
Beta0.49
1 Month Change22.20%
3 Month Change103.33%
1 Year Change45.82%
3 Year Change-51.20%
5 Year Changen/a
Change since IPO-56.69%

Recent News & Updates

Sep 02
Will Satsuma Pharmaceuticals (NASDAQ:STSA) Spend Its Cash Wisely?

Will Satsuma Pharmaceuticals (NASDAQ:STSA) Spend Its Cash Wisely?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

May 13
Here's Why We're Watching Satsuma Pharmaceuticals' (NASDAQ:STSA) Cash Burn Situation

Here's Why We're Watching Satsuma Pharmaceuticals' (NASDAQ:STSA) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Shareholder Returns

STSAUS PharmaceuticalsUS Market
7D5.8%-1.9%-5.2%
1Y45.8%2.9%-23.0%

Return vs Industry: STSA exceeded the US Pharmaceuticals industry which returned 2.9% over the past year.

Return vs Market: STSA exceeded the US Market which returned -23.1% over the past year.

Price Volatility

Is STSA's price volatile compared to industry and market?
STSA volatility
STSA Average Weekly Movement12.1%
Pharmaceuticals Industry Average Movement11.6%
Market Average Movement6.9%
10% most volatile stocks in US Market15.8%
10% least volatile stocks in US Market2.8%

Stable Share Price: STSA is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: STSA's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201625John Kollinshttps://www.satsumarx.com

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company’s lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Satsuma Pharmaceuticals Fundamentals Summary

How do Satsuma Pharmaceuticals's earnings and revenue compare to its market cap?
STSA fundamental statistics
Market CapUS$231.22m
Earnings (TTM)-US$60.67m
Revenue (TTM)n/a

0.0x

P/S Ratio

-3.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
STSA income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$60.67m
Earnings-US$60.67m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.92
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did STSA perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is STSA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for STSA?

Other financial metrics that can be useful for relative valuation.

STSA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDA-2.7x
PEG Ration/a

Price to Book Ratio vs Peers

How does STSA's PB Ratio compare to its peers?

STSA PB Ratio vs Peers
The above table shows the PB ratio for STSA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average1.2x
THRX Theseus Pharmaceuticals
1x-28.1%US$230.5m
MNKP.F Mallinckrodt
0.1xn/aUS$236.3m
MIST Milestone Pharmaceuticals
2.7x43.6%US$237.4m
RVLP RVL Pharmaceuticals
3.8x68.6%US$220.1m
STSA Satsuma Pharmaceuticals
3.2x10.0%US$231.2m

Price-To-Book vs Peers: STSA is expensive based on its Price-To-Book Ratio (3.2x) compared to the peer average (1.2x).


Price to Earnings Ratio vs Industry

How does STSA's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

Price-To-Book vs Industry: STSA is expensive based on its Price-To-Book Ratio (3.2x) compared to the US Pharmaceuticals industry average (1.7x)


Price to Book Ratio vs Fair Ratio

What is STSA's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

STSA PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio3.2x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate STSA's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of STSA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate STSA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate STSA's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Future Growth

How is Satsuma Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


10.0%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: STSA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: STSA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: STSA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: STSA is forecast to have no revenue next year.

High Growth Revenue: STSA is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if STSA's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Satsuma Pharmaceuticals performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-39.7%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: STSA is currently unprofitable.

Growing Profit Margin: STSA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: STSA is unprofitable, and losses have increased over the past 5 years at a rate of 39.7% per year.

Accelerating Growth: Unable to compare STSA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: STSA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (5%).


Return on Equity

High ROE: STSA has a negative Return on Equity (-84.04%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Satsuma Pharmaceuticals's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: STSA's short term assets ($72.5M) exceed its short term liabilities ($7.9M).

Long Term Liabilities: STSA's short term assets ($72.5M) exceed its long term liabilities ($70.0K).


Debt to Equity History and Analysis

Debt Level: STSA is debt free.

Reducing Debt: STSA had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: STSA has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: STSA has less than a year of cash runway if free cash flow continues to reduce at historical rates of 34.8% each year


Discover healthy companies

Dividend

What is Satsuma Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate STSA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate STSA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if STSA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if STSA's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as STSA has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

5.2yrs

Average management tenure


CEO

John Kollins (59 yo)

6.17yrs

Tenure

US$830,000

Compensation

Mr. John A. Kollins, MBA, has been Director, President and Chief Executive Officer of Satsuma Pharmaceuticals, Inc since July 2016. He served as Chief Business Officer and Senior Vice President of Transcep...


CEO Compensation Analysis

Compensation vs Market: John's total compensation ($USD830.00K) is below average for companies of similar size in the US market ($USD1.68M).

Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: STSA's management team is seasoned and experienced (5.2 years average tenure).


Board Members

Experienced Board: STSA's board of directors are considered experienced (5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

NasdaqGM:STSA Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
24 Nov 21BuyUS$15,837Commodore Capital LPCompany2,922US$5.42
22 Nov 21BuyUS$72,329Commodore Capital LPCompany13,204US$5.49
11 Nov 21BuyUS$104,332Commodore Capital LPCompany17,563US$6.05
08 Nov 21BuyUS$3,354Commodore Capital LPCompany560US$5.99
05 Nov 21BuyUS$54,642Commodore Capital LPCompany9,200US$5.95
02 Nov 21BuyUS$50,083Commodore Capital LPCompany8,880US$5.64
29 Oct 21BuyUS$254,957Commodore Capital LPCompany44,651US$5.71
28 Oct 21BuyUS$299,422Commodore Capital LPCompany54,663US$5.55
22 Oct 21BuyUS$329,442Commodore Capital LPCompany60,445US$5.51
20 Oct 21BuyUS$665,237Commodore Capital LPCompany128,243US$5.44
18 Oct 21BuyUS$784,845Commodore Capital LPCompany162,194US$4.87

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 25 shareholders own 77.89% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
18.72%
RA Capital Management, L.P.
5,914,252$43.3m0%0.98%
11.75%
Commodore Capital LP
3,711,286$27.2m0%5.32%
9.95%
New Enterprise Associates, Inc.
3,142,958$23.0m0%1.01%
9.32%
Samlyn Capital, LLC
2,944,255$21.6m5.33%0.44%
5.97%
TPG Capital, L.P.
1,885,939$13.8m0%0.07%
4.94%
Shin Nippon Biomedical Laboratories, Ltd.
1,561,719$11.4m-44.11%no data
3.9%
Vivo Capital, LLC
1,232,394$9.0m0%0.85%
2.4%
Columbia Management Investment Advisers, LLC
757,485$5.5m0.68%no data
2.07%
Ikarian Capital, LLC
653,448$4.8m0%1.74%
2.03%
The Vanguard Group, Inc.
640,364$4.7m-1.23%no data
0.98%
John Kollins
310,869$2.3m1.17%no data
0.77%
Morgan Stanley, Investment Banking and Brokerage Investments
243,457$1.8m1865.74%no data
0.75%
Dimensional Fund Advisors LP
236,535$1.7m7.58%no data
0.64%
Barclays Bank PLC, Securities Investments
202,478$1.5m0%no data
0.52%
Geode Capital Management, LLC
164,738$1.2m54.87%no data
0.48%
Walleye Capital LLC
151,428$1.1m-42.16%0.02%
0.48%
Citadel Advisors LLC
150,954$1.1m-18.67%no data
0.45%
Pivotal BioVenture Partners LLC
142,900$1.0m0%0.24%
0.43%
BlackRock, Inc.
137,240$1.0m2.32%no data
0.4%
Bridgeway Capital Management, LLC
127,300$931.8k8.53%0.02%
0.32%
Signal Iduna Asset Management GmbH
100,000$732.0k0%0.08%
0.21%
Boothbay Fund Management, LLC
64,840$474.6k0%0.02%
0.15%
JPMorgan Chase & Co, Brokerage and Securities Investments
46,998$344.0k0%no data
0.14%
State Street Global Advisors, Inc.
43,036$315.0k0%no data
0.12%
Northern Trust Global Investments
37,935$277.7k-2.12%no data

Company Information

Satsuma Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Satsuma Pharmaceuticals, Inc.
  • Ticker: STSA
  • Exchange: NasdaqGM
  • Founded: 2016
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$231.220m
  • Shares outstanding: 31.59m
  • Website: https://www.satsumarx.com

Number of Employees


Location

  • Satsuma Pharmaceuticals, Inc.
  • 400 Oyster Point Boulevard
  • Suite 221
  • South San Francisco
  • California
  • 94080
  • United States


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
STSANasdaqGM (Nasdaq Global Market)YesCommon SharesUSUSDSep 2019
1LVDB (Deutsche Boerse AG)YesCommon SharesDEEURSep 2019
1LVMUN (Boerse Muenchen)YesCommon SharesDEEURSep 2019

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/24 00:00
End of Day Share Price2022/09/23 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.